直接口服抗凝药在静脉血栓栓塞特殊人群中的临床应用

doi:10.12114/j.issn.1007-9572.2024.0541

摘要/Abstract

摘要： 直接口服抗凝药（DOACs）已被批准用于静脉血栓栓塞（VTE）的治疗和一、二级预防。近年来在临床中得到了稳定的应用并逐渐扩大适用范围。对于标准剂量DOACs虽然无需常规监测，但面对极端体质量、肝肾功能受损、高龄、妊娠与哺乳以及多种合并症的特殊患者群体，DOACs存在治疗的不确定性，可能需要调整剂量，或无法安全使用而给予肝素或维生素K拮抗剂（VKA）等传统抗凝药物。目前已有越来越多的学者针对这些特殊VTE患者群体开展研究，以评估DOACs在临床实践中的安全性和有效性。本综述整理分析了DOACs在特殊患者人群中的最新研究进展，为临床更加合理应用DOACs、优化抗凝策略提供证据和思路。

关键词: 抗凝药, 静脉血栓栓塞, 直接口服抗凝药, 特殊人群, 临床应用, 综述

Abstract:

Direct oral anticoagulants (DOACs) have been approved for the treatment and secondary prevention of venous thromboembolism (VTE), and have achieved stable application among clinicians in recent years, with an expanding scope of use. Although routine monitoring is not required for fixed-dose DOACs, in the context of special patient populations presenting with factors such as extreme body weight, impaired hepatic or renal function, advanced age, pregnancy and lactation, and multiple comorbidities, DOACs introduce therapeutic uncertainties, potentially necessitating dose adjustment or exclusion from use. In such cases, consideration should be given to the use of traditional anticoagulants such as heparin or vitamin K antagonist (VKA). Increasing numbers of studies have been conducted to assess the safety and effectiveness of DOACs in these special VTE patient populations across a wide range of settings. This review consolidates and analyzes the latest research progress on DOACs in these special patient populations, providing evidence and insights for more rational use of DOACs in clinical practice and optimizing anticoagulation strategies.

Key words: Anticoagulants, Venous thromboembolism, Direct oral anticoagulants, Special population, Treatment, Review

中图分类号:

R 973.2　R 543

肖瑶,万钧. 直接口服抗凝药在静脉血栓栓塞特殊人群中的临床应用[J]. 中国全科医学, 2025, 28(24): 3066-3071. DOI: 10.12114/j.issn.1007-9572.2024.0541.
XIAO Yao,WAN Jun. Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants[J]. Chinese General Practice, 2025, 28(24): 3066-3071. DOI: 10.12114/j.issn.1007-9572.2024.0541.

参考文献 40

[1]	STEVENS S M，WOLLER S C，KREUZIGER L B，et al. Antithrombotic therapy for VTE disease：second update of the CHEST guideline and expert panel report[J]. Chest，2021，160（6）：e545-608. DOI：10.1016/j.chest.2021.07.055.
[2]	MULDER F I，BOSCH F T M，YOUNG A M，et al. Direct oral anticoagulants for cancer-associated venous thromboembolism：a systematic review and meta-analysis[J]. Blood，2020，136（12）：1433-1441. DOI：10.1182/blood.2020005819.
[3]	GERVASO L，DAVE H，KHORANA A A. Venous and arterial thromboembolism in patients with cancer：JACC：CardioOncology state-of-the-art review[J]. JACC CardioOncol，2021，3（2）：173-190. DOI：10.1016/j.jaccao.2021.03.001.
[4]	HARKNESS W，PIPITONE O，JOSS J，et al. Observed apixaban anti-xa levels in obese patients[J]. Ann Pharmacother，2022：10600280221077158. DOI：10.1177/10600280221077158.
[5]	TALERICO R，POLA R，KLOK F A，et al. Direct-Acting Oral Anticoagulants in patients at extremes of body weight：a review of pharmacological considerations and clinical implications[J]. TH Open，2024，8（1）：e31-41. DOI：10.1055/s-0043-1776989.
[6]	CHEN A，STECKER E，WARDEN B A. Direct oral anticoagulant use：a practical guide to common clinical challenges[J]. J Am Heart Assoc，2020，9（13）：e017559. DOI：10.1161/JAHA.120.017559.
[7]	CROUCH A，NG T H，KELLEY D，et al. Multi-center retrospective study evaluating the efficacy and safety of apixaban versus warfarin for treatment of venous thromboembolism in patients with severe obesity[J]. Pharmacotherapy，2022，42（2）：119-133. DOI：10.1002/phar.2655.
[8]	COSTA O S，BEYER-WESTENDORF J，ASHTON V，et al. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism：analysis of electronic health record data[J]. J Thromb Thrombolysis，2021，51（2）：349-358. DOI：10.1007/s11239-020-02199-0.
[9]	ZHAO Y，GUO M X，LI D D，et al. Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients：an updated literature review[J]. Clin Appl Thromb Hemost，2023，29：10760296231153638. DOI：10.1177/10760296231153638.
[10]	PANDEY A K，EIKELBOOM J W. Direct oral anticoagulant dosing in extremes of body weight：time to revisit the guidelines?[J]. Thromb Haemost，2021，121（2）：118-120. DOI：10.1055/s-0040-1716753.
[11]	SPEED V，CZUPRYNSKA J，PATEL J P，et al. Use of direct oral anticoagulants for venous thromboembolism treatment at extremes of body weight，renal and liver function：an illustrated review[J]. Res Pract Thromb Haemost，2023，7（8）：102240. DOI：10.1016/j.rpth.2023.102240.
[12]	COSTACHE R S，DRAGOMIRICĂ A S，GHEORGHE B E，et al. Oral anticoagulation in patients with chronic liver disease[J]. Medicina，2023，59（2）：346. DOI：10.3390/medicina59020346.
[13]	LAWAL O D，ARONOW H D，HUME A L，et al. Venous thromboembolism，chronic liver disease and anticoagulant choice：effectiveness and safety of direct oral anticoagulants versus warfarin[J]. Res Pract Thromb Haemost，2023，8（1）：102293. DOI：10.1016/j.rpth.2023.102293.
[14]	MENICHELLI D，RONCA V，DI ROCCO A，et al. Direct oral anticoagulants and advanced liver disease：a systematic review and meta-analysis[J]. Eur J Clin Invest，2021，51（3）：e13397. DOI：10.1111/eci.13397.
[15]	SEMMLER G，POMEJ K，BAUER D J M，et al. Safety of direct oral anticoagulants in patients with advanced liver disease[J]. Liver Int，2021，41（9）：2159-2170. DOI：10.1111/liv.14992.
[16]	STEFFEL J，COLLINS R，ANTZ M，et al. 2021 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation[J]. Europace，2021，23（10）：1612-1676. DOI：10.1093/europace/euab065.
[17]	VAN ES N，COPPENS M，SCHULMAN S，et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism：evidence from phase 3 trials[J]. Blood，2014，124（12）：1968-1975. DOI：10.1182/blood-2014-04-571232.
[18]	CLINE L，GENEROSO E M G，D′APICE N，et al. Effectiveness and safety of direct oral anticoagulants in patients with venous thromboembolism and creatinine clearance < 30 mL/min[J]. J Thromb Thrombolysis，2023，55（2）：355-364. DOI：10.1007/s11239-022-02758-7.
[19]	WETMORE J B，HERZOG C A，YAN H，et al. Apixaban versus warfarin for treatment of venous thromboembolism in patients receiving long-term dialysis[J]. Clin J Am Soc Nephrol，2022，17（5）：693-702. DOI：10.2215/CJN.14021021.
[20]	POLI D，ANTONUCCI E，BERTÙ L，et al. Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs：Results from the prospective multicenter START2-Register Study[J]. Thromb Res，2019，183：28-32. DOI：10.1016/j.thromres.2019.08.024.
[21]	STÖLLBERGER C，FINSTERER J. Update on drug interactions with non-vitamin-K-antagonist oral anticoagulants for stroke prevention in elderly patients[J]. Expert Rev Clin Pharmacol，2021，14（5）：569-581. DOI：10.1080/17512433.2021.1908124.
[22]	VANASSCHE T，VERHAMME P，WELLS P S，et al. Impact of age，comorbidity，and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism：an analysis of the randomized，double-blind Hokusai-VTE trial[J]. Thromb Res，2018，162：7-14. DOI：10.1016/j.thromres.2017.12.005.
[23]	BAVALIA R，MIDDELDORP S，WEISSER G，et al. Treatment of venous thromboembolism in special populations with direct oral anticoagulants[J]. J Thromb Haemost，2020，120（6）：899-911. DOI：10.1055/s-0040-1710314.
[24]	DAEI M，KHALILI H，HEIDARI Z. Direct oral anticoagulant safety during breastfeeding：a narrative review[J]. Eur J Clin Pharmacol，2021，77（10）：1465-1471. DOI：10.1007/s00228-021-03154-5.
[25]	BATES S M，RAJASEKHAR A，MIDDELDORP S，et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism：venous thromboembolism in the context of pregnancy[J]. Blood Adv，2018，2（22）：3317-3359. DOI：10.1182/bloodadvances.2018024802.
[26]	RASKOB G E，VAN ES N，VERHAMME P，et al. Edoxaban for the treatment of cancer-associated venous thromboembolism[J]. N Engl J Med，2018，378（7）：615-624. DOI：10.1056/NEJMoa1711948.
[27]	DI NISIO M，VAN ES N，CARRIER M，et al. Extended treatment with edoxaban in cancer patients with venous thromboembolism：a post-hoc analysis of the Hokusai-VTE Cancer study[J]. J Thromb Haemost，2019，17（11）：1866-1874. DOI：10.1111/jth.14561.
[28]	YOUNG A M，MARSHALL A，THIRLWALL J，et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism：results of a randomized trial（SELECT-D）[J]. J Clin Oncol，2018，36（20）：2017-2023. DOI：10.1200/JCO.2018.78.8034.
[29]	FRERE C，FARGE D，SCHRAG D，et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism：2022 updated systematic review and meta-analysis of randomized controlled trials[J]. J Hematol Oncol，2022，15（1）：69. DOI：10.1186/s13045-022-01289-1.
[30]	CHATANI R，YAMASHITA Y，MORIMOTO T，et al. Transition of management strategies and long-term outcomes in cancer-associated venous thromboembolism from the warfarin era to the direct oral anticoagulant era[J]. Eur J Intern Med，2024，123：72-80. DOI：10.1016/j.ejim.2024.01.012.
[31]	SIKORSKA M，CHMIEL J，PAPUGA-SZELA E，et al. Apixaban versus vitamin K antagonists in patients with antiphospholipid syndrome：a cohort study[J]. J Cardiovasc Pharmacol，2024，84（1）：36-44. DOI：10.1097/FJC.0000000000001578.
[32]	FRANCO-MORENO A，IZQUIERDO-MARTÍNEZ A，ANCOS-ARACIL C. Rethinking the use of direct oral anticoagulants for secondary thromboprophylaxis in patients with thrombotic antiphospholipid syndrome[J]. Drug Discov Ther，2024，18（4）：213-219. DOI：10.5582/DDT.2024.01050.
[33]	KHAIRANI C D，BEJJANI A，PIAZZA G，et al. Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes：meta-analysis of randomized trials[J]. J Am Coll Cardiol，2023，81（1）：16-30. DOI：10.1016/j.jacc.2022.10.008.
[34]	ZUILY S，COHEN H，ISENBERG D，et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome：Guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis[J]. J Thromb Haemost，2020，18（9）：2126-2137. DOI：10.1111/jth.14935.
[35]	KONSTANTINIDES S V，MEYER G，BECATTINI C，et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society（ERS）[J]. Eur Heart J，2020，41（4）：543-603. DOI：10.1093/eurheartj/ehz405.
[36]	HOSOKAWA K，ABE K，TSUTSUI H. Use of direct oral anticoagulants prevents increase in pulmonary vascular resistance and incidence of clinical worsening in patients with chronic thromboembolic pulmonary hypertension[J]. Thromb Res，2019，180：43-46. DOI：10.1016/j.thromres.2019.05.018.
[37]	JEONG I，FERNANDES T，ALOTAIBI M，et al. Direct oral anticoagulant use and thrombus detection in patients with chronic thromboembolic pulmonary hypertension referred for pulmonary thromboendarterectomy[J]. European Respiratory Society，2019，54（suppl 63）：OA5161. DOI：10.1183/13993003.congress-2019.oa5161.
[38]	SALAZAR A M，PANAMA G，KIM A G，et al. Clinical outcomes between direct oral anticoagulants versus vitamin K antagonists in chronic thromboembolic pulmonary hypertension：a systematic review and meta-analysis[J]. Curr Probl Cardiol，2024，49（3）：102377. DOI：10.1016/j.cpcardiol.2024.102377.
[39]	BUNCLARK K，NEWNHAM M，CHIU Y D，et al. A multicenter study of anticoagulation in operable chronic thromboembolic pulmonary hypertension[J]. J Thromb Haemost，2020，18（1）：114-122. DOI：10.1111/jth.14649.
[40]	中华医学会呼吸病学分会肺栓塞与肺血管病学组，中国医师协会呼吸医师分会肺栓塞与肺血管病工作组，全国肺栓塞与肺血管病防治协作组，等. 慢性血栓栓塞性肺动脉高压诊断与治疗指南（2024版）[J]. 中华医学杂志，2024，104（24）：2200-2221. DOI：10.3760/cma.j.cn112137-20240116-00117.